Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...

After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have ...

Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the ...

Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events ...

Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.

Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene ...

The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth ...

Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...